OTCM
IMCDY
Market cap6.53bUSD
Oct 08, Last price
55.38USD
1D
0.34%
1Q
13.62%
IPO
23.48%
Name
IMCD NV
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in Rotterdam, the Netherlands, in 1995, IMCD N.V. operates as a leading global distributor and marketer of a diverse range of specialized chemicals and premium ingredients. Its extensive operations span across the Netherlands, the wider European continent, the Middle East, Africa, both North and South America, and the Asia-Pacific region. IMCD's comprehensive product portfolio serves numerous industries. For the pharmaceutical, agrochemical, and nutraceutical sectors, it provides essential active ingredients, excipients, formulation components, and compounds for regulated synthesis. Within personal care and cosmetics, the company supplies a wide array of offerings including active substances, UV filters, rheology modifiers, thickeners, emulsifiers, emollients, colorants, fragrances, and various functional additives for skin and hair products. Industrial applications benefit from resins, binders, functional fillers, and specialized solvents. Additionally, IMCD offers solutions for the food and beverage industry, focusing on enhancing taste, improving texture, and boosting nutritional value. The company also supports the energy sector with base oils, fuel and lubricant additives, and related fluids, alongside a broad spectrum of bio-based chemicals, catalysts, intermediates, and organic building blocks for various chemical processes.
Related entities
Subsidiaries (9)
IMCD Benelux B.V.
IMCD Deutschland GmbH
IMCD Finance B.V.
IMCD FRANCE SAS
IMCD Group B.V.
IMCD POLSKA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
IMCD UK LIMITED
IMCD BENELUX
IMCD PORTUGAL - PRODUTOS QUÍMICOS, LDA
Key people
A. B. Smalbraak
Independent Chairman of the Supervisory Board · since 2021
Independent Vice Chairman of the Supervisory Board · since 2023
Andreas Igerl
President - Europe, Middle East & Africa · since 2025
Marcus Jordan
Chief Executive Officer, Member of the Management Board · since 2025
Olivier Champault
Business Group Director Advanced Materials · since 2024
John Robinson
Business Group Director Pharmaceutical · since 2000
Frank Schneider
Business Group Director Coatings and Construction · since 2006
Fenna van Zanten
Group Director - Mergers and Acquisitions · since 2024
Hans Kooijmans
Chief Financial Officer, Member of the Management Board · since 1996
Amy Hebert
Independent Member of the Supervisory Board · since 2020
Independent Member of the Supervisory Board · since 2022
Dorthe Mikkelsen
Independent Member of the Supervisory Board · since 2023
Headquarters & legal address
Wilhelminaplein 32
Rotterdam 3072DE
NL
Rotterdam 3072DE
NL
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||